iiinova — where your digital self keeps evolving

Mark Faghy @profmarkfaghy.bsky.social · 22/09/2026

Our animation highlighting the key results from ERASE_LC

0207

Mark Faghy @profmarkfaghy.bsky.social · 22/09/2026

Our short animation to descirbe the results and findings.

45220

Mark Faghy @profmarkfaghy.bsky.social · 22/09/2026

🚀 The key message: ERASE-LC shows that administering IV remdesivir to people with LC is feasible, acceptable, and well tolerated. Signals suggest therapeutic promise, but only a properly powered RCT will determine whether remdesivir provides meaningful benefit.

1287

Mark Faghy @profmarkfaghy.bsky.social · 22/09/2026

These findings should be interpreted cautiously, but they provide a strong rationale for further investigation.

1212

Mark Faghy @profmarkfaghy.bsky.social · 22/09/2026

📊 Although not designed to prove efficacy, exploratory analyses showed some very encouraging signals. We observed improvements in many patient-reported outcomes and Clinical assessments, including physical function tests such as the 6-minute walk test.

1232

Mark Faghy @profmarkfaghy.bsky.social · 22/09/2026

🛡️ Safety was a primary consideration. There were no severe adverse reactions were reported, and almost all participants successfully completed treatment. This is an important first step in determining whether IV antiviral treatment strategies can be tested in larger trials.

1202

Mark Faghy @profmarkfaghy.bsky.social · 22/09/2026

These findings demonstrate that delivering a multi-day IV antiviral intervention in this population is both practical and acceptable.

1222

Mark Faghy @profmarkfaghy.bsky.social · 22/09/2026

🔬 We recruited 73 adults with confirmed Long COVID across two UK sites. Key feasibility findings: ✅ 97% completed the full 5-day remdesivir course ✅ 96% completed follow-up assessments ✅ High engagement with outcome measures and symptom tracking

1233

Mark Faghy @profmarkfaghy.bsky.social · 22/09/2026

Our hypothesis was driven by ongoing questions around viral persistence and its potential role in symptom burden. #LongCOVID #COVIDResearch

1222

Mark Faghy @profmarkfaghy.bsky.social · 22/09/2026

📢 Our paper is published in Oxford Open Immunology: The ERASE_LC trial evaluated whether a 5-day course of intravenous remdesivir is feasible, safe, and acceptable for people living with Long COVID. This is the first study to specifically examine remdesivir as a treatment for LC.

17223

Mark Faghy @profmarkfaghy.bsky.social · 30/07/2026

Not eligible yourself? A repost could make a huge difference by helping this survey reach people with lived experience of Long COVID. Thank you for supporting patient-centred research and the next generation of health researchers. 💙 #LongCOVID #LongCovidResearch #Rehabilitation #PatientVoice

151

Mark Faghy @profmarkfaghy.bsky.social · 30/07/2026

The study, Factors Influencing Experiences of Rehabilitation Among Adults with Long COVID: An Explanatory Sequential Mixed-Methods Study, aims to better understand what helps, what hinders, and how rehabilitation services are experienced by people with Long COVID.

130

Mark Faghy @profmarkfaghy.bsky.social · 29/04/2026

8️⃣ To reinforce our patient focused approach - a number of the articles co-authors are patients. They always make sure we ask the right questions..

0274

Mark Faghy @profmarkfaghy.bsky.social · 29/04/2026

7️⃣ Take‑home message Long COVID is not a single disease but a complex, multisystem condition. Advancing care will depend on mechanism‑driven research, collaboration across disciplines, and sustained long‑term investment.

14418

Mark Faghy @profmarkfaghy.bsky.social · 29/04/2026

6️⃣ Future recommendations We call for: 🔹 Better patient phenotyping and stratification 🔹 Longitudinal, mechanistic cohort studies 🔹 Integration of multi‑omics and imaging approaches 🔹 Standardised definitions and outcome measures 🔹 Closer alignment between basic science and clinical research

1202

Mark Faghy @profmarkfaghy.bsky.social · 29/04/2026

5️⃣ This matters because.. Without a clear mechanistic understanding, progress on diagnostics, targeted treatments, and clinical trials remains slow and fragmented.

1182

Mark Faghy @profmarkfaghy.bsky.social · 29/04/2026

4️⃣ Cross‑cutting issues The authors emphasise: • Biological heterogeneity between patients • Overlapping mechanisms across organ systems • The lack of definitive biomarkers • Challenges in case definitions and stratification

1193

Mark Faghy @profmarkfaghy.bsky.social · 29/04/2026

3️⃣ Key mechanistic areas covered 🦠 Viral persistence and reservoirs 🧬 Immune dysregulation & chronic inflammation 🧠 Neurological and neurocognitive mechanisms 🫀 Cardiovascular and endothelial dysfunction ⚡ Mitochondrial and metabolic impairment 🧪 Autoimmunity and microclot hypotheses

1214

Mark Faghy @profmarkfaghy.bsky.social · 29/04/2026

2️⃣ Scope of the review The paper brings together evidence across multiple systems and disciplines, reflecting the heterogeneous and multisystem nature of long COVID.

1183

Mark Faghy @profmarkfaghy.bsky.social · 29/04/2026

1️⃣ Aim This review aims to synthesise current evidence on the mechanisms and pathophysiology underlying long COVID, highlighting what is known, what remains uncertain, and why progress has been challenging.

1182

Mark Faghy @profmarkfaghy.bsky.social · 20/10/2025

We’re really happy to be sharing our work at the @longcovidweb.bsky.social symposia in the wonderful city of St John’s, Newfoundland 🇨🇦 If you’re attending the event either online or in person, please come and say hello!!

A picture of the landscape of St John’s - Newfoundland.

A poster presented at an academic conference.

0121

Mark Faghy @profmarkfaghy.bsky.social · 20/10/2025

This update is therefore to let all of you in the community know that we are still here and continuing to work hard in our bid to help the many millions of people living with Long Covid.

2160

Mark Faghy @profmarkfaghy.bsky.social · 20/10/2025

Once the results have been fully analysed and then checked by other independent researchers (a process called peer review) we will let you know the outcome. This process takes a long time.

171

Mark Faghy @profmarkfaghy.bsky.social · 20/10/2025

Next steps will be to analyse the data to see how feasible it is for people with Long Covid to receive this drug and look for any suggestions as to how the drug has affected participants.

150

Mark Faghy @profmarkfaghy.bsky.social · 20/10/2025

Sorry for the silence: The ERASE-LC trial is making steady progress. All participants have now received their infusions of remdesivir and completed their post-treatment testing.

1347

Mark Faghy @profmarkfaghy.bsky.social · 24/06/2025

So good to have you join us for the day!! Lots of great discussions and ideas.. now to find ways to implement them!

0115

Mark Faghy @profmarkfaghy.bsky.social · 19/06/2025

And just like that we have completed ERASE in Derby A patient-led study with @derbyuni.bsky.social, University Hospitals Derby and Burton, Peninsula CTU and Exeter University to help people with #LongCovid Thanks to everyone, especially the participants who gave so much to this work.

Three people stood looking directly at a camera.

An exercise bike next to laboratory equipment.

3164

Reposted by Mark Faghy

Binita Kane @binitakane.bsky.social · 23/05/2025

Our global effort to raise the urgency of research into Long Covid in children published in The ERJ ⬇️ Huge thanks to @buonsenso.bsky.social and @laelyonker.bsky.social for leading on this. #longcovidkids @longcovidkids.bsky.social publications.ersnet.org/content/erj/...

27838

Mark Faghy @profmarkfaghy.bsky.social · 18/05/2025

We’re recruiting a fixed term (3 years) researcher in clinical exercise science and Long COVID. If you want to join a team that is at the forefront of the pathophysiology/lived experience research then please get in touch. Please share with your network! www.derby.ac.uk/jobs/current...

derby.ac.uk

Researcher in Clinical Exercise Science (Long COVID)

Exciting opportunity to contribute to impactful Long COVID research.

03225

Mark Faghy @profmarkfaghy.bsky.social · 16/05/2025

54 Patients.. 270 infusion days.. A whole lot of tea and biscuits.. @derbyuni.bsky.social and @UHDBTrust are completing their last round of ERASE infusions today! Great teamwork from all involved, and big thanks to the participants for making the last 8 months so enjoyable.

An infusion bag hanging from a drip stand.

041

Reposted by Mark Faghy

Billy Hanlon @bhanlon15.bsky.social · 28/04/2025

University of Derby: 'University embarks on ground-breaking long Covid research project' 'The £1.25 million trial, which is the first of its kind in the UK, is exploring whether anti-viral medications can be used as an effective treatment option...' www.marketingderby.co.uk/news/univers...

marketingderby.co.uk

University embarks on ground-breaking long Covid research project - Marketing Derby

A ground-breaking research project led by the University of Derby, which aims to find a treatment for symptoms of long Covid, is underway...

0206

Reposted by Mark Faghy

Sammie McFarland @sammiemc.bsky.social · 29/04/2025

Access has been a “postcode lottery”, says @profmarkfaghy.bsky.social, an associate professor in respiratory physiology at @derbyuni.bsky.social and policy advisor for @longcovidkids.bsky.social He adds that children and young people are at a “disadvantage from the outset”.

101

Reposted by Mark Faghy

northernsi.bsky.social @northernsi.bsky.social · 28/03/2025

Thank you @profmarkfaghy.bsky.social and your brilliant team 🙌 You might be interested in this, @jonathandaviesmp.bsky.social #LongCovid #Derbyshire

142

Mark Faghy @profmarkfaghy.bsky.social · 20/03/2025

Please if you haven't already consider signing this petition to urge important investment in paediatric research in #longcovid Without research, we cannot progress the mechanistic knowledge needed to develop diagnostic tests and treatments! you.38degrees.org.uk/petitions/in...

you.38degrees.org.uk

Invest in Long Covid & M.E. Research: Thousands of Children DISABLED, DISCHARGED, & HIDDEN FROM VIEW

• Five years after the start of the Covid pandemic, thousands remain severely ill - Many housebound or often bedbound, unable to attend school, work, or take part in daily life.  Disabled, discha...

1168

Reposted by Mark Faghy

Long COVID Physio @longcovidphysio.bsky.social · 12/03/2025

Scientists are investigating whether anti-viral drugs could provide an effective treatment for LongCovid “It is vital research for the people who are living with LongCovid now but also the people who will go on to develop LC in the future” @profmarkfaghy.bsky.social t.co/kfLzV0B0fy

t.co

https://www.itv.com/news/2025-03-11/not-forgotten-fresh-hope-for-long-covid-cure-five-years-on-from-pandemic

084

Mark Faghy @profmarkfaghy.bsky.social · 12/03/2025

Ondine was a big voice and a strong advocate for #Longcovid and will be sorely missed by everyone. I shared many lovely moments with Ondine as part of our involvement in the @covidinquiryuk I am gutted and lost for words! We will continue to advocate with Ondine looking down!

2298

Mark Faghy @profmarkfaghy.bsky.social · 12/03/2025

Here is our piece that was featured on @itvnews.bsky.social yesterday, which talks about #longcovid research. www.itv.com/news/2025-03...

itv.com

062

Mark Faghy @profmarkfaghy.bsky.social · 13/02/2025

What a fine piece of academic literature this is from Amy Proal @resiapretorius.bsky.social and others: www.thelancet.com/journals/lan... Science overload that paves the way for the development of future diagnostic investigations and potential treatments for LC!

thelancet.com

Targeting the SARS-CoV-2 reservoir in long COVID

There are no approved treatments for post-COVID-19 condition (also known as long COVID), a debilitating disease state following SARS-CoV-2 infection that is estimated to affect tens of millions of peo...

2196

Mark Faghy @profmarkfaghy.bsky.social · 10/02/2025

Decided to get back on the socials after a short break due to personal issues where my time and attention was needed elsewhere.. we've still been working hard but just not public facing but I'm back and we have some important updates and information to share over the course of the next few weeks!

0161